19 August

Aurevia advances a first-wave urology programme for patients with unmet need

Aurevia Life Sciences is concentrating a growing share of R&D on urology, an area where many patients still cycle through limited options.

The current wave includes programmes in benign prostatic hyperplasia, kidney-stone support and overactive bladder, developed with qualified manufacturing and clinical partners.

We will share further milestones as studies mature. This information is for professional and public awareness and is not a substitute for medical advice.